ARTICLE
8 February 2024

FDA/CDRH's Take On The Growing Importance Of Transparency In AI/ML-Enabled Medical Devices

FL
Foley & Lardner

Contributor

Foley & Lardner LLP looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With over 1,100 lawyers in 24 offices across the United States, Mexico, Europe and Asia, Foley approaches client service by first understanding our clients’ priorities, objectives and challenges. We work hard to understand our clients’ issues and forge long-term relationships with them to help achieve successful outcomes and solve their legal issues through practical business advice and cutting-edge legal insight. Our clients view us as trusted business advisors because we understand that great legal service is only valuable if it is relevant, practical and beneficial to their businesses.
Beyond traditional regulatory concerns, the U.S. Food and Drug Administration (FDA) is currently navigating the challenges of usability...
United States Technology

Beyond traditional regulatory concerns, the U.S. Food and Drug Administration (FDA) is currently navigating the challenges of usability, equity, performance bias, continuous learning, and accountability in response to an ever increasing number of AI/ML devices. The FDA's Center for Devices and Radiological Health's (CDRH) proactive action plan, unveiled in 2018, underscores the agency's commitment to responsible AI/ML device integration. The emphasis on transparency, patient-centered approaches, and collaborative regulatory science initiatives reflects the continuously evolving landscape.

The United States Food and Drug Administration (FDA) is reviewing an increasing number of applications for AI/ML devices, with the number receiving FDA marketing authorization nearing seven hundred as of October 2023. AI/ML devices have unique considerations during their development and use, including those for usability, equity of access, management of performance bias, the potential for continuous learning, and stakeholder (manufacturer, patient, caregiver, healthcare provider, etc.) accountability. These considerations impact not only the responsible development and use of AI/ML devices but also the regulation of such devices. FDA's Center for Devices and Radiological Health (CDRH) recognizes these unique considerations and released an action plan for AI/ML devices in January 20218. Among its numerous aims, this action plan highlights CDRH's commitment to promoting transparency of AI/ML devices by fostering a patient-centered approach, while also collaborating with stakeholders on regulatory science efforts.

www.nature.com/...

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More